Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

Clinical Pharmacokinetics

Volumn 48, Issue 4, 2009, Pages 273-280

  Gatta, Maria Del Mar Fernández De ^a   Buelga, Dolores Santos ^a   Navarro, Amparo Sánchez ^a   Dominguez Gil, Alfonso ^a,b   García, Maria Jose ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; CUMULATIVE FRACTION OF RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROBABILITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STRAIN IDENTIFICATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; STAPHYLOCOCCUS; VANCOMYCIN;

EID: 66849128255     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200948040-00005     Document Type: Article

References (33)

1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 March; 34 (6): 730-51
2. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003 August; 37 (3): 382-9
3. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55: 436-44
4. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay and health care costs. Clin Infect Dis 2006; 42 (2 Suppl.): 83S-89S
5. Diaz Granados C, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191: 588-95
6. Fernández de Gatta MM, Fruns I, Hernández JM, et al. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies. Clin Pharm 1993; 12: 515-20
7. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Inter Med 2006 Oct; 23 (166): 2138-44
8. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmaco-kinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharma-cokinet 2006; 45: 755-73
9. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 (1 Suppl.): 16S-23S
10. McDonald LC. Trends in antimicrobial resistance in health-care associated pathogens and effect on treatment. Clin Infect Dis 2006; 42 (Suppl.): 65S-71S
11. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis 2005 Dec; 53 (4): 281-7
12. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43 (13): 925-42
13. Fernández de Gatta MM, Revilla N, Calvo MV, et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007; 33: 279-85
14. Buelga DS, Fernández de Gatta MM, Herrera EV, et al. Population pharma-cokinetic analysis ofvancomycinin patients with hematological malignancies. Antimicrob Agents Chemother 2005 Dec; 49 (12): 4934-41
15. Kantzanou K, Tassios PT, Tseleni-Kotsovili A, et al. Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1999; 43: 729-31
16. European Society of Clinical Microbiology and Infectious Diseases. The European Committee on Antimicrobial Susceptibility Testing - Eucast [online]. Available from URL: http://www.eucast.org [Accessed 2008 Jan]
17. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55 (5): 601-7
18. Machain L. SimulAr: Montecarlo simulation in Excel [online]. Available from URL: http://www.simularsoft.com.ar/ [Accessed 2007 Nov]
19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
20. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45 (3 Suppl.): 177S-183S
21. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases of America. Clin Infect Dis 2008 Jan; 46: 155-64
22. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007; 45 (3 Suppl.): 191S-195S
23. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38 (5): 865-9
24. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008 Jan; 52: 24-36
25. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006 Oct; 130 (4): 947-55
26. Lewis J, Ellis MW. Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management. Curr Opin Infect Dis 2007; 20: 568-73
27. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008 Jan 15; 46 (2): 193-200
28. Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. IntJ Antimicrob Agents 2002; 20 (5): 326-32
29. Schentag JJ. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit Care Med 2001; 29 (4 Suppl.): 100S-107S
30. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007 Jun; 29 (6): 1107-15
31. Lodise P, Lomaestro B, Graves J, et al. Larger vancomycin doses (>4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008 Apr; 52 (4): 1330-6
32. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008 Jul; 62 (1): 168-71
33. Fernández de Gatta MM, Calvo MV, Hernández JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996; 60: 332-4